The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India
Subscribe To Our Newsletter & Stay Updated
